Future Role of New Negative Inotropic Agents in the Era of Established Surgical Myectomy for Symptomatic Obstructive Hypertrophic Cardiomyopathy

Abstract

For 60 years hypertrophic cardiomyopathy (HCM) has periodically been encumbered by controversy and uncertainty about its management strategies, due largely to heterogeneous clinical presentation and relatively low prevalence in cardiovascular practice.1–3 Nevertheless, HCM has now achieved recognition as a contemporary and treatable disease, a stature unanticipated in earlier eras.1–3.